Early trial results hail Moderna's COVID-19 vaccine as 94.5% effective
Data also show that mRNA-1273 remains stable at 2–8°, the temperature of a standard home or medical refrigerator, for 30 days.
For the second Monday in a row, the light at the end of the tunnel - an effective vaccine against COVID-19 - burns a little brighter with Phase III interim results of Moderna's vaccine candidate demonstrating it is 94.5% effective.
The US biotechnology company's vaccine, mRNA-1273, which is going through a Phase III clinical trial (COVE), has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
The study enrolled more than 30,000 participants in the US, including communities that have historically been under-represented in clinical research and have been disproportionately affected by COVID-19. Half of the participants received a placebo, whereas the other half received two doses of the vaccine candidate.
The primary endpoint of the Phase III study (the prevention of symptomatic COVID-19 disease) is based on the analysis of COVID-19 cases confirmed and adjudicated starting 2 weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5%.
A secondary endpoint (prevention of severe COVID-19 disease) analysed severe cases of COVID-19 and included 11 severe cases in this first interim analysis. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.
Stéphane Bancel, Chief Executive Officer of Moderna, described the event as a "pivotal moment" in their effort to develop a safe and efficacious COVID-19 vaccine.
Unlike the Pfizer vaccine candidate, which has logistical challenges — it needs to be stored at about -70 °C — Moderna's vaccine remains stable at 2–8 °C, the temperature of a standard home or medical refrigerator, for 30 days. Furthermore, mRNA-1273 remains stable at -20 °C for up to 6 months, at refrigerated conditions for up to 30 days and at room temperature for up to 12 hours.
Although the trial will continue to accrue additional data relevant to safety and efficacy, the company intends to submit for an Emergency Use Authorization (EUA) with the US FDA in the coming weeks.
Pending approval, Moderna expects to have approximately 20 million doses of mRNA-1273 ready to ship in the US by the end of 2020 and remains on track to manufacture 500 million to 1 billion doses globally in 2021.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance